Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AXSM NASDAQ:ELVN NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$136.30+1.0%$116.22$9.25▼$148.83$10.85B0.871.58 million shs710,656 shsAXSMAxsome Therapeutics$236.72+0.6%$237.45$96.09▼$260.19$12.16B0.6772,449 shs243,370 shsELVNEnliven Therapeutics$52.69+1.9%$43.70$14.78▼$52.95$3.21B0.241.31 million shs293,861 shsSMMTSummit Therapeutics$15.05-2.7%$15.63$12.55▼$30.98$11.67B-1.263.97 million shs1.48 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.79%-5.11%+39.73%+11.06%+1,427.86%AXSMAxsome Therapeutics+3.06%-5.81%-7.80%+27.73%+109.44%ELVNEnliven Therapeutics+1.69%+1.59%+12.14%+17.70%+124.91%SMMTSummit Therapeutics+1.11%-2.58%+10.42%-26.75%-39.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$136.30+1.0%$116.22$9.25▼$148.83$10.85B0.871.58 million shs710,656 shsAXSMAxsome Therapeutics$236.72+0.6%$237.45$96.09▼$260.19$12.16B0.6772,449 shs243,370 shsELVNEnliven Therapeutics$52.69+1.9%$43.70$14.78▼$52.95$3.21B0.241.31 million shs293,861 shsSMMTSummit Therapeutics$15.05-2.7%$15.63$12.55▼$30.98$11.67B-1.263.97 million shs1.48 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.79%-5.11%+39.73%+11.06%+1,427.86%AXSMAxsome Therapeutics+3.06%-5.81%-7.80%+27.73%+109.44%ELVNEnliven Therapeutics+1.69%+1.59%+12.14%+17.70%+124.91%SMMTSummit Therapeutics+1.11%-2.58%+10.42%-26.75%-39.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.81Moderate Buy$148.548.98% UpsideAXSMAxsome Therapeutics 2.95Moderate Buy$259.059.43% UpsideELVNEnliven Therapeutics 2.86Moderate Buy$69.1731.27% UpsideSMMTSummit Therapeutics 2.44Hold$26.9779.23% UpsideCurrent Analyst Ratings BreakdownLatest ELVN, AXSM, SMMT, and ABVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral7/15/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$290.007/9/2026ABVXAbivax Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$165.00 ➝ $175.007/9/2026ELVNEnliven Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $64.007/8/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$290.007/7/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$302.00 ➝ $304.007/2/2026ABVXAbivax Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$135.00 ➝ $155.007/1/2026ABVXAbivax Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$187.007/1/2026ELVNEnliven Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $80.006/30/2026ABVXAbivax HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026ABVXAbivax GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AAXSMAxsome Therapeutics$708.24M17.20N/AN/A$1.75 per share135.27ELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/ASMMTSummit TherapeuticsN/AN/AN/AN/A$0.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/14/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.73N/A50.69N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)ELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)Latest ELVN, AXSM, SMMT, and ABVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026ELVNEnliven Therapeutics-$0.38N/AN/AN/AN/AN/A8/10/2026Q2 2026SMMTSummit Therapeutics-$0.26N/AN/AN/A$0.11 millionN/A8/3/2026Q2 2026AXSMAxsome Therapeutics-$0.8575N/AN/AN/A$221.62 millionN/A5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million5/1/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25AXSMAxsome Therapeutics2.271.391.32ELVNEnliven TherapeuticsN/A40.3240.32SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AXSMAxsome Therapeutics81.49%ELVNEnliven Therapeutics95.08%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAXSMAxsome Therapeutics20.60%ELVNEnliven Therapeutics3.00%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.77 millionN/ANot OptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableELVNEnliven Therapeutics5060.90 million59.08 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableELVN, AXSM, SMMT, and ABVX HeadlinesRecent News About These CompaniesSummit to Divest Late-Stage Antibiotic Drug to Biossil in $105M DealJuly 15 at 9:51 AM | zacks.com119,655 Shares in Summit Therapeutics PLC $SMMT Bought by Y Intercept Hong Kong LtdJuly 9, 2026 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Hold" by BrokeragesJuly 9, 2026 | marketbeat.comSMMT Stock Price PredictionJuly 4, 2026 | 247wallst.comSummit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by Wall Street ZenJuly 4, 2026 | americanbankingnews.comHsbc Holdings PLC Buys New Shares in Summit Therapeutics PLC $SMMTJuly 1, 2026 | marketbeat.comSummit Therapeutics: High-Volatility, Catalyst-Driven Binary BetJune 22, 2026 | seekingalpha.comSummit Therapeutics PLC $SMMT Shares Bought by Baker BROS. Advisors LPJune 18, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Purchases 3,810,000 SharesJune 13, 2026 | insidertrades.comWhy is SMMT stock tumbling today?June 10, 2026 | msn.comSummit Therapeutics Announces Proposed Public Offering of Common StockJune 9, 2026 | businesswire.comSummit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comMizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform TechJune 7, 2026 | 247wallst.comThe Era of the One-Size-Fits-All Cancer Drug Is EndingJune 6, 2026 | wsj.comSummit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial DataJune 5, 2026 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) CFO Manmeet Singh Soni Buys 50,000 SharesJune 5, 2026 | insidertrades.comSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare ConferenceJune 4, 2026 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)June 4, 2026 | theglobeandmail.comAssessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return ProfileJune 4, 2026 | finance.yahoo.comAll You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to BuyJune 4, 2026 | zacks.comSummit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress - SlideshowJune 3, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026Abivax: Wall Street Catches Up to the DataBy Chris Markoch | July 7, 2026ELVN, AXSM, SMMT, and ABVX Company DescriptionsAbivax NASDAQ:ABVX$136.30 +1.39 (+1.03%) As of 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Axsome Therapeutics NASDAQ:AXSM$236.72 +1.46 (+0.62%) As of 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Enliven Therapeutics NASDAQ:ELVN$52.69 +0.96 (+1.86%) As of 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Summit Therapeutics NASDAQ:SMMT$15.05 -0.42 (-2.72%) As of 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
